LAI and first episode schizophrenia

Long-acting injected antipsychotics may have a role in the treatment of first episode schizophrenia, according to US investigators (JAMA Psychiatry 2015;doi:10.1001/jamapsychiatry.2015.0270).
Their 12-month trial showed that long-acting risperidone was associated with a lower rate of exacerbations or relapse (5 vs 33 per cent, superior control of …

More details...

Breast cancer and schizophrenia

Breast cancer may be more common among women with schizophrenia, leading some to suggest that raised prolactin secondary to the use of antipsychotics may be a contributory factor.
That may be the case, say researchers from Belgium and the UK, but their systematic review indicates that …

More details...

Pros and cons of lithium

The British Journal of Psychiatry has published two studies of lithium therapy, the first a retrospective claims study in the US, showed that about one year’s treatment with lithium reduced the risk of dementia by 23% in individuals aged at least 50 years with bipolar …

More details...

Experience of mental health crisis ‘variable’ says CQC

The quality of care experienced by a person during a mental health crisis can vary greatly depending on where they are and what help they require, the Care Quality Commission has found (www.cqc.org.uk/ content/new-report-looking-peoples-experience-care-during-mental-health-crisis).
Its report Right Here, Right Now also documents important shortcomings in the …

More details...

Dementia care experience shared

Windsor and Maidenhead CCG has shared its experience of a programme to improve the care of people with dementia and their carers via the NICE shared learning database (www.nice.org.uk/sharedlearning/living-with-dementia-%E2%80%93-improving-care-home-care).
The CCG describes how implementing NICE guidance to train care home staff helped it to improve knowledge …

More details...

NHS announces review of deaths in people with learning disabilities

NHS England, the Healthcare Quality Improvement Partnership (HQIP) and the University of Bristol are to undertake a three-year review of premature deaths among people with learning disabilities (www.england.nhs.uk/2015/06/18/reduce-prem-mortality-ld/).
Led by the University of Bristol’s Norah Fry Research Centre, the National Learning Disability Mortality Review Programme (www.hqip.org.uk/the-learning-disabilities-mortality-review-programme) …

More details...

One-year outcomes for migraine monoclonal

Amgen’s monoclonal antibody AMG 334 offers a sustained reduction in monthly migraine-days after one year’s treatment, according to results presented by the company at the 57th Annual Scientific Meeting of the American Headache Society in Washington DC (www.biospace.com/News/amgen-presents-open-label-extension-data-from/382147/source=MoreNews).
The data come from a non-blinded extension of …

More details...

Fast track for schizophrenia cognitive impairment drug

Forum Pharmaceuticals has announced that the FDA has granted fast track status to encenicline, its treatment for cognitive impairment associated with schizophrenia (www.biospace.com/News/forum-pharma-snags-fast-track-status-for/382166/source=MoreNews).
Encenicline, an α7 nicotinic receptor agonist, is currently in Phase III development. The COGNITIV SZ trial will evaluate its efficacy as a pro-cognitive …

More details...

DMD treatment steps closer in US

The regulatory approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) has moved closer after developer Sarepta Therapeutics announced completion of its marketing authorisation submission to the US Food and Drug Administration (www.biospace.com/News/sarepta-completes-nda-submission-to-fda-for/382986/source=MoreNews).
Eteplirsen enables production of a functional internally truncated dystrophin protein in …

More details...

Orphan drug status for spinocerebellar ataxia drug

The European Commission has granted orphan status to a treatment for spinocerebellar ataxia (www.biospace.com/News/bioblast-pharma-receives-orphan-drug-designation/382885/source=MoreNews).
Cabaletta, under development by biotech company BioBlast, is a chemical chaperone that prevents pathological aggregation of proteins within cells. It has also been shown to have activity in animal models of other …

More details...

Web design and marketing agency Leamington Spa